Chimeric IL‐6/4R‐LL37 Engineered Macrophages Achieve Synchronized Inflammation Control and Antimicrobial Defence in Sepsis
Open Access
- 7 August 2026
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (60)
Abstract
Treatment of septic patients is confronted with complex immune dysregulation: excessive pro‐inflammatory responses trigger cytokine storm leading to organ damage and high mortality, while concurrent and persistent immune dysfunction manifesting as T cell exhaustion, monocyte and macrophage functional suppression, and impaired antigen presentation significantly increases the risk of secondary infections. Current clinical therapeutic strategies can effectively control infection and cytokine storm, but fail to resolve persistent T cell exhaustion, which is a critical determinant of poor long‐term survival in sepsis patients. This study reported a multifunctional engineered macrophage therapeutic strategy based on in situ LNP delivery of IL‐6/4 fusion protein and LL37 antimicrobial peptide mRNA. The IL‐6/4 fusion blocks IL‐6 mediated pro‐inflammatory signaling and activates IL‐4 mediated anti‐inflammatory pathways, reducing inflammatory injury and promoting tissue repair. LL37 antimicrobial peptide disrupts bacterial membranes to reduce bacterial burden while modulating immune responses. In sepsis mouse models, engineered macrophages significantly improved survival rates, reduced histopathological damage and organ bacterial burden, and effectively restored T cell and macrophage functions, achieving infection control, inflammation modulation, and immune reconstitution. These findings demonstrate the substantial clinical translational potential of this engineered macrophage approach for precision sepsis treatment.Keywords
Funding Information
- National Natural Science Foundation of China (82225031)
- National Natural Science Foundation of China (82172464)
- National Natural Science Foundation of China (81972086)
- National Natural Science Foundation of China (82572782)
- National Key Research and Development Program of China (2023YFC2509600)
This publication has 37 references indexed in Scilit:
- Development of a chimeric cytokine receptor that captures IL-6 and enhances the antitumor response of CAR-T cellsCell Reports Medicine, 2024
- Defining IL‐6 levels in healthy individuals: A meta‐analysisJournal of Medical Virology, 2020
- Using Large Datasets to Understand NanotechnologyAdvanced Materials, 2019
- PECAM-1 directed re-targeting of exogenous mRNA providing two orders of magnitude enhancement of vascular delivery and expression in lungs independent of apolipoprotein E-mediated uptakeJournal of Controlled Release, 2018
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)JAMA, 2016
- Epidemiology, Patterns of Care, and Mortality for Patients With Acute Respiratory Distress Syndrome in Intensive Care Units in 50 CountriesJAMA, 2016
- Why have clinical trials in sepsis failed?Trends in Molecular Medicine, 2014
- Immunosuppression in Patients Who Die of Sepsis and Multiple Organ FailureJAMA, 2011
- Cecal ligation and puncture: the gold standard model for polymicrobial sepsis?Trends in Microbiology, 2011
- Syndecans as cell surface receptors: Unique structure equates with functional diversityMatrix Biology, 2011